Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | HRH1 | P35367 | 3/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.71 |
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.71 |
| ▸ | DRD1 | P21728 | 2/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | HRH2 | P25021 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL15719828 | 0.84 | LMNA (0.97) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL6118138 | 0.84 | SLC6A4 (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL29350100 | 0.84 | SLC6A4 (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL17004048 | 0.84 | SLC6A4 (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL34282 | 0.84 | SLC6A4 (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| SCHEMBL14732502 | 0.84 | SLC6A4 (0.57) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| SCHEMBL14723083 | 0.83 | SLC6A4 (0.55) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| SCHEMBL14723391 | 0.83 | SLC6A4 (0.55) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL41765 | 0.83 | LMNA (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 | |
| Imipramine SCHEMBL28759733 | 0.83 | LMNA (1.00) | SLC6A4LMNAMAPTHRH1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 726 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | claimed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | claimed |
| WO-2023282544-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | 국립암센터 | 2023-01-12 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20160303103-A1 | COMPOUNDS THAT TREAT MALARIA AND PREVENT MALARIA TRANSMISSION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2016-10-20 | — | — | US | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| EP-1096927-A1 | COMPOSITION FOR TREATMENT OF STRESS | Massachusetts Institute of Technology (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000003701-A1 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-27 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| EP-0386117-B1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INST TECHNOLOGY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1992000103-A1 | PHARMACEUTICAL PREPARATIONS | BEECHAM GROUP PLC (GB) | 1992-01-09 | — | — | WO | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303103-A1 | COMPOUNDS THAT TREAT MALARIA AND PREVENT MALARIA TRANSMISSION | ICMT, MAVS, G6PD | SLC6A4 3685/4885LMNA 2419/4885MAPT 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.